Given the theranostic potential of emerging new-generation FAPI radiopharmaceuticals (79) and the growing innovation in the field of anti-FAP pseudopeptides (80, 81), the demand for PET imaging of the tumor microenvironment is expected to increase significantly. The gene discussed is FAP; the disease is neoplasm.